title: Clinical results of piezoelectric gallstone lithotripsy.
abstract: The safety and efficacy of piezoelectric extracorporeal shockwave lithotripsy in the treatment of symptomatic gallbladder stones were evaluated in 53 consecutively treated patients. All treatments were performed as outpatients without anesthesia; over 95 per cent of 109 treatments were performed without analgesia or sedation. Ursodeoxycholic acid was administered post-treatment. Seventy per cent of patients had multiple sessions. Cumulative stone-free rates of 38 per cent at 6 months, 65 per cent at 12 months, and 75 per cent at 15 months were achieved. There was no difference in eventual stone clearance between patients with single stones less than 20 mm diameter, single stones greater than or equal to 20 mm diameter, or multiple (two or three) stones, although patients with single smaller stones required significantly fewer total shocks to become stone-free (P = .02). Stone clearance correlated with estimated stone volume. Biliary pain occurred in 62 per cent of patients after treatment but ceased in stone-free patients. Biliary complications of pancreatitis (7.5%) and choledocholithiasis (3.8%) were successfully treated by endoscopic papillotomy. Nonbiliary complications were virtually nonexistent. Three patients (5.7%) had elective cholecystectomy. Results indicate that piezoelectric lithotripsy is a safe, minimally painful treatment that, in conjunction with oral bile acids, can produce stone-free rates of 75 to 100 per cent in selected patients.
authors.affiliation: Rush-Presbyterian-St. Luke's Medical Center, Department of General Surgery, Chicago, IL 60612.
authors.forename: D J
authors.initials: DJ
authors.lastname: Deziel
authors.forename: D M
authors.initials: DM
authors.lastname: Jensen
authors.forename: J H
authors.initials: JH
authors.lastname: Faibisoff
authors.forename: A
authors.initials: A
authors.lastname: Silver
authors.forename: B
authors.initials: B
authors.lastname: Silver
authors.forename: S M
authors.initials: SM
authors.lastname: Sabesin
mesh_terms: D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000209:etiology; D002769:Cholelithiasis / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D003085:Colic / Q000209:etiology; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D014580:Ursodeoxycholic Acid